Cytarabine (U-19920A) - 10mM in Water, high purity , CAS No.147-94-4(water)

Item Number
C408830
Grouped product items
SKUSizeAvailabilityPrice Qty
C408830-1ml
1ml
Available within 4-8 weeks(?)
Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience!
$59.90

DNA/RNA Synthesis Inhibitors

Basic Description

Specifications & Purity10mM in Water
Storage TempStore at -80°C
Shipped InIce chest + Ice pads
GradeMoligand™
Product Description

Information

Cytarabine (U-19920A) Cytarabine (U-19920A, Cytarabin, Ara-C, Arabinofuranosyl Cytidine, Cytosine β-D-arabinofuranoside, Cytosine arabinoside, NSC 63878, NSC 287459) is an antimetabolic agent and DNA synthesis inhibitor with IC50 of 16 nM in wild-type C
In vitro

Cytarabine (AraC) is phosphorylated into a triphosphate form (Ara-CTP) involving deoxycytidine kinase (dCK), which competes with dCTP for incorporation into DNA, and then blocks DNA synthesis by inhibiting the function of DNA and RNA polymerases. Cytarabine displays a higher growth inhibitory activity towards wild-type CCRF-CEM cells compared to other acute myelogenous leukemia (AML) cells with IC50 of 16 nM. Increasing concentrations of Cytarabine (IC50 of 0.69 μM) results in decreased metabolic activity of sensitive rat leukemic cell line RO/1, and the cell toxity can be highly enhanced by transfection with human wt dCK (IC50 of 0.037 μM) but not the inactive, alternatively spliced dCK forms. Cytarabine apparently induces apoptosis of rat sympathetic neurons at 10 μM, of which 100 μM shows the highest toxicity and kills over 80% of the neurons by 84 hours, involving the release of mitochondrial cytochrome-c and the activation of caspase-3, and the toxicity can be attenuated by p53 knockdown and delayed by bax deletion.

In vivo

Cytarabine is highly effective against acute leukaemias, which causes the characteristic G1/S blockage and synchronization, and increases the survival time for leukaemic Brown Norway rats in a weak dose-related fashion indicating that the use of higher dosages of Cytarabine does not contribute to its antileukaemic effectiveness in man. Cytarabine (250 mg/kg) also causes placental growth retardation and increases placental trophoblastic cells apoptosis in the placental labyrinth zone of the pregnant Slc:Wistar rats, which increases from 3 hour after the treatment and peaks at 6 hour before returning to control levels at 48 hour, with remarkably enhanced p53 protein, p53 trancriptional target genes such as p21, cyclinG1 and fas and caspase-3 activity.
Cell Data

cell lines:

Concentrations:~100 μM

Incubation Time:24, 48 and 72 hours

Powder Purity:≥99%

Associated Targets(Human)

MDM2 Tchem E3 ubiquitin-protein ligase Mdm2 (1 Activities)
Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

Names and Identifiers

Canonical SMILES NC1=NC(=O)N(C=C1)C2OC(CO)C(O)C2O
Molecular Weight 243.22

Certificates

Certificate of Analysis(COA)

Enter Lot Number to search for COA:

Safety and Hazards(GHS)

Pictogram(s) GHS08,   GHS07
Signal Warning
Hazard Statements

H317:May cause an allergic skin reaction

H361:Suspected of damaging fertility or the unborn child

Precautionary Statements

P261:Avoid breathing dust/fume/gas/mist/vapors/spray.

P280:Wear protective gloves/protective clothing/eye protection/face protection.

P201:Obtain special instructions before use.

P272:Contaminated work clothing should not be allowed out of the workplace.

P202:Do not handle until all safety precautions have been read and understood.

Related Documents

FAQs and Articles

Solution Calculators